Literature DB >> 9166845

Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase.

S M Wu1, D W Stafford, L D Frazier, Y Y Fu, K A High, K Chu, B Sanchez-Vega, J Solera.   

Abstract

The human gene for gamma-glutamyl carboxylase is 13 kb in length and contains 15 exons. Transcription starts at a cytosine 217 base pair upstream of the first codon. There are two major transcripts in all tissues examined. They are distinguished by the presence of an Alu sequence in the 3' nontranslated end of the longer species. Relative mRNA levels for 12 bovine tissues are presented.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9166845

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  16 in total

Review 1.  Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors:  Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Compound heterozygosity of novel missense mutations in the gamma-glutamyl-carboxylase gene causes hereditary combined vitamin K-dependent coagulation factor deficiency.

Authors:  Dhouha Darghouth; Kevin W Hallgren; Rebecca L Shtofman; Amel Mrad; Youssef Gharbi; Ahmed Maherzi; Radhia Kastally; Sophie LeRicousse; Kathleen L Berkner; Jean-Philippe Rosa
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

3.  gamma -Glutamyl carboxylation: An extracellular posttranslational modification that antedates the divergence of molluscs, arthropods, and chordates.

Authors:  Pradip K Bandyopadhyay; James E Garrett; Reshma P Shetty; Tyler Keate; Craig S Walker; Baldomero M Olivera
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

4.  Genetic mutation of vitamin K-dependent gamma-glutamyl carboxylase domain in patients with calcium oxalate urolithiasis.

Authors:  Jiankun Qiao; Tao Wang; Jun Yang; Jihong Liu; Xiaoxin Gong; Xiaolin Guo; Shaogang Wang; Zhangqun Ye
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-10-11

5.  Effect of GGCX gene polymorphism on the responses of serum undercarboxylated osteocalcin and bone turnover markers after treatment with vitamin K2 (menatetrenone) among postmenopausal Thai women.

Authors:  Thawee Songpatanasilp; La-or Chailurkit; Suwannee Chantprasertyothin; Boonsong Ongphiphadhanakul; Nimit Taechakraichana
Journal:  J Bone Miner Metab       Date:  2011-02-23       Impact factor: 2.626

6.  Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.

Authors:  Janne Cadamuro; Benjamin Dieplinger; Thomas Felder; Igor Kedenko; Thomas Mueller; Meinhard Haltmayer; Wolfgang Patsch; Hannes Oberkofler
Journal:  Eur J Clin Pharmacol       Date:  2009-12-18       Impact factor: 2.953

Review 7.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

Review 8.  Hereditary combined deficiency of the vitamin K-dependent clotting factors.

Authors:  Mariasanta Napolitano; Guglielmo Mariani; Mario Lapecorella
Journal:  Orphanet J Rare Dis       Date:  2010-07-14       Impact factor: 4.123

Review 9.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors:  Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines.

Authors:  Naoki Ueda; Hidenori Shiraha; Tatsuya Fujikawa; Nobuyuki Takaoka; Yutaka Nakanishi; Mayumi Suzuki; Noriyuki Matsuo; Shigetomi Tanaka; Shin-Ichi Nishina; Masayuki Uemura; Akinobu Takaki; Yasushi Shiratori; Kazuhide Yamamoto
Journal:  Mol Oncol       Date:  2008-06-20       Impact factor: 6.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.